EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer

Shan-Shan Fan, Yi-Min Chen, Wen-Da Chen, Zheng-Hua Sun, Jian Yin, Mei Xie, Pu Wu

Asian Journal of Andrology · 2026

DOI: 10.4103/aja202591 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Asian Journal of Andrology, 2026. Verfasst von Shan-Shan Fan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As immunotherapy continues to push the envelope, it has had transformative success in malignancies such as melanoma and lung cancer. However, in contrast to these cancers, implementing immunotherapy in prostate cancer (PCa) still presents considerable difficulties. PCa itself is not sensitive to immunotherapy. The low response rate of PCa to immunotherapy cannot be attributed to a single mechanism. Instead, it results from the interplay of multiple adverse factors. These include the tumor’s inherently low immunogenicity and the highly immunosuppressive properties of its tumor microenvironment. Taken together, these features create a “perfect storm” that severely limits the efficacy of immunotherapy. In this review, we comprehensively assess the latest advances in PCa immunotherapy, encompassing cancer vaccines, immune checkpoint inhibitors (ICIs), chimeric antigen receptor T cell (CAR-T) therapy, and various combination regimens. We also summarize their limited efficacy observed in clinical practice to date. Furthermore, we explore the underlying mechanisms contributing to the limited effectiveness of immunotherapy in PCa, with a focus on intrinsic molecular features, the immunosuppressive microenvironment, and key signaling pathways. Through an in-depth review of previous studies, we aim to provide a theoretical foundation and strategic guidance to enhance the effectiveness of immunotherapy for PCa and to facilitate the development and translation of more targeted and effective immunotherapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsImmunotherapyImmune Checkpoint InhibitorsHumansMaleCancer VaccinesTumor MicroenvironmentImmunotherapy, Adoptive

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapyprostate cancertherapeutic cancer vaccinestumor microenvironment

Substanzen

Cancer VaccinesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China.
  • School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
  • Key Laboratory of Elemene Anti-Cancer Traditional Chinese Medicine and Zhejiang Provincial Collaborative Innovation Center of Traditional Chinese Medicine, Hangzhou Normal University, Hangzhou 311121, China.

Zitieren

APA

Fan, S. S., Chen, Y. M., Chen, W. D., Sun, Z. H., Yin, J., Xie, M., & Wu, P. (2026). Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer. Asian Journal of Andrology. https://doi.org/10.4103/aja202591

Vancouver

Fan SS, Chen YM, Chen WD, Sun ZH, Yin J, Xie M, et al. Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer. Asian Journal of Andrology. 2026. doi:10.4103/aja202591

BibTeX
@article{Fan2026,
  author = {Fan, Shan-Shan and Chen, Yi-Min and Chen, Wen-Da and Sun, Zheng-Hua and Yin, Jian and Xie, Mei and Wu, Pu},
  title = {Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer},
  journal = {Asian Journal of Andrology},
  year = {2026},
  doi = {10.4103/aja202591}
}
Kostenlos starten →